The present invention relates to replacement valves for improving the cardiac function of a patient suffering from cardiac valve dysfunction, such as aortic valve regurgitation or aortic stenosis. More particularly, the present invention relates to heart valve prostheses that provide improved durability and are particularly well-suited for percutaneous delivery.
Heart valve replacement has become a routine surgical procedure for patients suffering from valve regurgitation or stenotic calcification of the leaflets. While certain procedures may be performed using minimally-invasive techniques (so-called “keyhole” techniques), the vast majority of valve replacements entail full sternotomy and placing the patient on cardiopulmonary bypass. Traditional open surgery inflicts significant patient trauma and discomfort, requires extensive recuperation times, and may result in life-threatening complications.
To address these concerns, within the last decade efforts have been made to perform cardiac valve replacements using minimally-invasive techniques. In these methods, laparoscopic instruments are employed to make small openings through the patient's ribs to provide access to the heart. While considerable effort has been devoted to such techniques, widespread acceptance has been limited by the clinician's ability to access only certain regions of the heart using laparoscopic instruments.
Still other efforts have been focused on percutaneous transluminal delivery of replacement cardiac valves to solve the problems presented by traditional open surgery and minimally-invasive surgical methods. In such methods, a valve prosthesis is compacted for delivery in a catheter and then advanced, for example, through an opening in the femoral artery and through the descending aorta to the heart, where the prosthesis then is deployed in the aortic valve annulus. Although transluminal techniques have attained widespread acceptance with respect to delivery of stents to restore vessel patency, only mixed results have been obtained with respect to percutaneous delivery of relatively more complicated valve prostheses.
One such example of a previously-known heart valve prosthesis is described in U.S. Pat. No. 6,454,799 to Schreck. The prosthesis described in that patent comprises a fabric-based heart valve disposed within a plastically deformable wire-mesh base, and is delivered via expansion of a balloon catheter. One drawback with balloon catheter delivery of the prosthetic valve is that the valve leaflets may be damaged when compressed between the balloon and the base during deployment. In addition, because balloon expandable structures tend to experience some recoil following balloon deflation, perivalvular leaks may develop around the circumference of the valve prosthesis.
Accordingly it would be desirable to provide a percutaneously-deliverable valve prosthesis that reduces the risk of leaflet damage during deployment of the prosthesis. It further would be desirable to provide a valve prosthesis that reduces the risk of perivalvular leaks resulting from recoil of the prosthesis following deployment.
U.S. Pat. No. 6,027,525 to Suh, et al. describes a valve prosthesis comprising a series of self-expanding units affixed to a polymeric cover and having a valve disposed therein. Such devices are not suitable for cardiac valve replacement because of the limited ability to compact the valve disposed within the prosthesis. Moreover, such valve prostheses would be particularly undesirable for treating aortic valve defects, because the polymeric cover would obscure the ostia of the coronary arteries, both disrupting blood flow to the coronary arteries and preventing subsequent catheterization of those arteries. Accordingly, it would be desirable to provide a valve prosthesis that is self-expanding, yet permits the valve to be compacted to a greater degree than previously-known designs.
U.S. Pat. No. 6,682,559 to Myers, et al. also describes a valve prosthesis having an essentially tubular design. One drawback of such configurations is that relatively large horizontal forces arise along the coaptation edges of the leaflets and are transmitted to the commissural points. These forces may adversely affect the durability of the leaflets and lead to valve failure. In view of this, it would be desirable to provide a valve wherein the center of coaptation of the leaflets may be selected so as to reduce horizontal forces applied to coaptation edges of the leaflets and commissural points, thereby improving durability of the valve. In addition, it would be desirable to provide a valve design that more uniformly distributes horizontal forces over the coaptation edges of the leaflets, rather than concentrating those forces at the commissural points.
In an effort to more nearly recreate the force distribution along the leaflets of natural tissue valves, some previously-known valve designs include circular base portions having longitudinal projections that function as anchors for the commissural points, such as described in U.S. Pat. No. 5,855,601 to Bessler, et al. and U.S. Pat. No. 6,582,462 to Andersen, et al.
While the valve prostheses of Bessler and Andersen may be readily collapsed for delivery, those designs are susceptible to problems once deployed. For example, the longitudinal projections of such prostheses may not provide sufficient rigidity to withstand compressive forces applied during normal movements of the heart. Deformation of the commissural anchors may result in varied forces being imposed on the commissures and leaflets, in turn adversely impacting functioning of the leaflets. In addition, because the exteriors of the foregoing valve prostheses are substantially cylindrical, the prostheses are less likely to adequately conform to, and become anchored within the valve annulus anatomy during deployment. As a result, cyclic loading of the valve may result in some slippage or migration of the anchor relative to the patient's anatomy.
In view of the foregoing, it would be desirable to provide a valve that is capable of conforming to a patient's anatomy while providing a uniform degree of rigidity and protection for critical valve components.
It also would be desirable to provide a valve prosthesis having portions that are capable of deforming circumferentially to adapt to the shape of the pre-existing valve annulus, but which is not susceptible to deformation or migration due to normal movement of the heart.
It further would be desirable to provide a valve prosthesis having a multi-level component that is anatomically shaped when deployed, thereby enhancing anchoring of the valve and reducing the risk of migration and perivalvular leaks.
It still further would be desirable to provide a valve prosthesis wherein the valve body is configured to facilitate fabrication, and to assume a reduced delivery profile compared to previously known designs without damaging the functional components of the valve body.
In view of the foregoing, it is an object of the present invention to provide a valve prosthesis that overcomes the drawbacks of previously-known designs, and which may be implanted using open surgical, minimally invasive, or percutaneous implantation techniques.
It is yet another object of the present invention to provide a percutaneously-deliverable valve prosthesis that exhibits a markedly reduced delivery profile over known designs.
It is also an object of the present invention to provide a percutaneously-deliverable valve prosthesis that reduces the risk of damage to the leaflets or other functional components of the valve body during delivery and deployment of the prosthesis.
It is a further object of this invention to provide a valve prosthesis that reduces the risk of perivalvular leaks resulting from elastic recoil of the prosthesis following deployment.
It is another object of the present invention to provide a valve prosthesis that is self-expanding and permits ready access to adjoining anatomical structures, such as the coronary arteries.
It is a still further object of the present invention to provide a valve in which the center of coaptation of the leaflets may be selected so as to reduce horizontal forces applied to coaptation edges of the leaflets and commissural points, thereby improving durability of the valve.
In addition, it is an object of this invention to provide a valve design that more uniformly distributes forces over the coaptation edges of the leaflets, rather than concentrating those forces at the commissural points.
It is yet another object of this invention to provide a valve that is anatomically shaped, provides a uniform high degree of rigidity and protection for critical valve components, and which is less susceptible to deformation arising from normal movement of the heart.
It is an object of the present invention to provide a valve prosthesis having portions that are capable of deforming circumferentially to adapt to the shape of the pre-existing valve annulus, but which is not susceptible to deformation or migration due to normal movement of the heart.
It is also an object of this invention to provide a valve prosthesis having a multi-level component that is anatomically shaped when deployed, thereby enhancing anchoring of the valve and reducing the risk of migration and perivalvular leaks.
It is a further object of the present invention to provide a valve prosthesis wherein a valve is disposed within a rigid portion of a multilevel frame, so that valve area and function are not impaired, but inflow and/or outflow portions of the multilevel frame are capable of conforming to patient anatomy anomalies.
It is a further object of the present invention to provide a valve prosthesis that facilitates alignment of the heart valve prosthesis with the direction of blood flow.
These and other objects of the present invention are accomplished by providing a heart valve prosthesis wherein a self-expanding multi-level frame supports a valve body comprising a skirt and plurality of coapting leaflets. The frame has a contracted delivery configuration, in which the prosthesis may be stored within a catheter for percutaneous delivery, and an expanded deployed configuration having an asymmetric hourglass shape.
In a first preferred embodiment, the valve body skirt and leaflets are constructed of porcine, bovine, equine or other mammalian tissue, such as pericardial tissue, and are sewn, welded, molded or glued together so as to efficiently distribute forces along the leaflets and to the frame. In a particularly preferred embodiment, the skirt comprises three sections of mammalian tissue that are joined along adjacent edges, so that the tissue folds easily to a collapsed delivery profile without bunching.
Alternatively, the skirt of the valve body may comprise a synthetic or polymetric material, such as Dacron, expanded polytetrafluoroethylene (“ePTFE”), or other suitable synthetic graft material. The valve body leaflets may be constructed of porcine, bovine, equine or other mammalian tissue, such as pericardial tissue, and are sewn, welded, molded or glued to the skirt so as to efficiently distribute forces along the leaflets and to the frame. The use of synthetic or polymeric materials for the valve skirt in conjunction with mammalian tissue leaflets may offer distinct advantages. In particular, the synthetic material may provide the same structural properties as the mammalian tissue but at reduced thickness, thereby enabling the valve body to be collapsed to a smaller delivery profile. Alternatively, the leaflets also may comprise a synthetic or polymeric material.
In accordance with the principles of the present invention, the frame comprises multiple levels, including a proximal conical inflow section, a constriction region and a flared distal outflow section. Each of the inflow and outflow sections is capable of deforming to a non-circular cross-section to conform to the patient's anatomy, while the constriction region is configured to retain a circular cross-section that preserves proper functioning of the valve body.
The frame comprises a plurality of cells having a pattern that varies along the length of the frame to provide a high degree of anchoring and alignment of the valve prosthesis. The cell pattern further is selected to provide a uniform diameter where the commissural joints of the leaflets are attached to the frame, while permitting the inflow and outflow regions to expand to conform to the patient's anatomy. In this manner, optimal functioning of the valve body may be obtained even though the frame may be deployed in anatomies having a range of sizes. In addition, the frame resists deformation caused by movement of the heart and enables a functional portion of the valve body to be disposed supra-annularly to the native valve, with a portion of the valve prosthesis extending into the native valve annulus.
In one embodiment suitable for aortic valve replacement, the valve body comprises a skirt coupled to three leaflets. The components may be formed of animal pericardial tissue or synthetic material, and are sewn, glued, welded or molded together. The lateral ends of the leaflets include enlarged regions that are folded to both form the commissural joints and fasten the commissural joints to the frame. The skirt and leaflets further are configured so that the joints align with contours of the cell pattern of the frame.
In a preferred embodiment, the commissural joints are affixed to the frame at locations above the area of coaptation, to provide a selectable center of coaptation of the leaflets. This design provides a more efficient delivery configuration because the commissures are not compressed against the leaflets when the valve prosthesis is reduced to the contracted delivery configuration. Additionally, by lengthening the distance to the commissures, the design mimics the functioning of natural tissue valves by distributing forces along the coaptation edges and reducing horizontal forces transmitted to the commissural joints.
In alternative embodiments, the valve body of the present invention may include a sewing ring in lieu of the frame to facilitate surgical implantation, and may employ as few as two and as many as four leaflets.
Methods of making and using the valve prostheses of the present invention are also provided.
The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference numerals refer to like parts throughout, and in which:
The present invention is directed to a heart valve prosthesis having a self-expanding frame that supports a valve body. In a preferred embodiment, the frame has a tri-level asymmetric hourglass shape with a conical proximal section, an enlarged distal section and a constriction region having a predefined curvature when the frame is deployed. In the context of the present application, the proximal section constitutes the “inflow” portion of the valve prosthesis and is disposed in the aortic annulus of the patient's left ventricle, while the distal section constitutes the “outflow” portion of the valve prosthesis and is positioned in the patient's ascending aorta.
In a preferred embodiment the valve body comprises three leaflets that are fastened together at enlarged lateral end regions to form commissural joints, with the unattached edges forming the coaptation edges of the valve. The leaflets are fastened to a skirt, which is in turn affixed to the frame. The enlarged lateral end regions of the leaflets permit the material to be folded over to enhance durability of the valve and reduce stress concentration points that could lead to fatigue or tearing of the leaflets. The commissural joints are mounted above the plane of the coaptation edges of the valve body to minimize the contracted delivery profile of the valve prosthesis, while the configuration of the edges permits uniform stress distribution along the coaptation edges.
Referring to
Frame 12 preferably includes multiple levels, including outflow section 15, inflow section 16 and constriction region 17. As depicted in the enlarged view of
The cell pattern of frame 12 also enables the frame to expand to the tri-level asymmetric hourglass shape depicted in
Enlarged outflow section has nominal deployed diameter Do, inflow section has nominal deployed diameter DI, and constriction region has deployed substantially fixed diameter Dc. The conical shape of the inflow region and smooth transitions between adjacent sections of frame 12 are expected to be particularly advantageous in directing blood flow through the valve body with little or no turbulence, as compared to step changes in diameter observed for surgically implanted replacement valves.
The above-described cell pattern permits each of the inflow and outflow sections of frame 12 to expand to a diameter within a range of deployed diameters, while retaining constriction region 17 at a substantially constant diameter. Thus, for example, outflow diameter Do may range from 30 to 55 mm, while inflow diameter DI may vary from 19 to 34 mm. Illustratively, frame 12 may be manufactured in four sizes having a range of diameters Do, DI and Dc as set forth in Table 1 below:
Advantageously, these four frame sizes are expected to cover a wide range of patient anatomies, while requiring construction of only two sizes of valve bodies (22 and 24 mm). Compared to previously-known commercially available surgical valves, which vary from approximately 17 mm to 31 mm in one millimeter increments, it is expected that the above four sizes of valve prosthesis of the present invention could be used for more than 75% of the patient population, thus greatly reducing the costs associated with manufacturing and inventorying large numbers of parts.
When configured as a replacement for an aortic valve, inflow section 16 extends into and anchors within the aortic annulus of a patient's left ventricle and outflow section 15 is positioned in the patient's ascending aorta. Importantly, the configuration of outflow section 15 is expected to provide optimal alignment of the valve body with the direction of blood flow. In addition, the cell pattern of outflow section 15 also serves to anchor the outflow section in the patient's ascending aorta to prevent lateral movement or migration of frame 12. As depicted in
Still referring to
As depicted in
Referring to
Referring now to
In an alternative preferred embodiment, leaflets 22 are formed from animal pericardial tissue as described above, while skirt 21 is cut from a sheet of synthetic or polymer material, such as Dacron, ePTFE, or other similar material as known in the art. In this case, skirt 21 has a thickness of between 0.004″ and 0.012″, and more preferably between 0.006″ and 0.008″, and may thus be compressed to a substantially smaller delivery profile. Alternatively, skirt 21 and leaflets 22 may be constructed of a synthetic or polymeric material.
Leaflet 22 includes enlarged lateral ends 30 and 31 disposed at either end of free edge 32, and body 33. Free edge 32 forms coaptation edge 25 of the finished valve body 14, while lateral ends 30 and 31 are folded and joined to adjacent leaflets to form commissures 24. In accordance with one aspect of the present invention, free edges 32 assume the form of catenaries when the valve body is affixed to frame 12, thereby providing uniform loading along the length of the coaptation edge in a manner similar to a suspension bridge. Body 33 is joined to skirt 21 as described below. Lateral ends 30 and 31 illustratively are shown in
In the embodiment of
End tabs 39 are folded over the ends of the proximal-most row of cells of frame 12 to secure skirt 21 to the frame and seal against perivalvular bypass flows (see
It has been observed that when panels 21a-21c are cut conjoined from a single piece of animal pericardium, the skirt has a tendency to bunch-up or “accordion” when the valve body is collapsed to its reduced delivery configuration. However, applicants have discovered that if panels 21a-21c are severed along fold lines h in
As a still further alternative, skirt 21 may be formed of a synthetic or polymeric material, such as Dacron, ePTFE, or similar material selected for its properties and biocompatibility. As opposed to leaflets 22, which provide a mechanical function through movement, skirt 21 functions primarily to create a seal to prevent perivalvular leaks. Accordingly, a thin synthetic material may be used in place of thicker mammalian tissue to serve this purpose. As a result, the device may be compacted to a reduced delivery profile by virtue of the decreased volume of the skirt. For example, use of a synthetic skirt with a valve body having tissue-based leaflets may enable the device to fit within a catheter having even less than an 18 French diameter.
Referring to
Reinforcing tabs 38 are folded along lines g, h and i to form seams 43 comprising a double thickness of tissue, or in the case of separate panels 21a-21c, joined to form seams along tabs 38. Next, the leaflet assembly is attached to skirt 21 along the bottom edges of bodies 33 of the leaflets to form joints 44. At this stage of the assembly, prior to attaching reinforcing tab 40 to 41 and the remaining seam 42 of leaflets 22, the valve body appears as depicted in
Referring to
In
Referring to
When completed assembled to frame 12, valve body 14 is affixed to frame 12 along the edges of flaps 36 of the commissures, end tabs 39, leaflet seams 42, reinforcing tab seams 43 and joints 44. In this manner, forces imposed on leaflets 22, commissures 24 and joints 44 are efficiently and evenly distributed over the valve body and transferred to frame 12, thus reducing stress concentration and fatigue of the valve body components. Moreover, the use of multiple thicknesses of material along seams 42 and 43 is expected to provide a highly durable valve body that will last for many years once implanted in a patient.
In accordance with another aspect of the present invention, the center of coaptation of leaflets 22 is a distance L below the point at which the commissures are affixed to the frame, as shown in
the leaflets require only minimal pressure to open and have a rapid closing time.
the valve demonstrates better washing dynamics when open, i.e., less turbulence along the free edges of the leaflets.
the valve provides a more uniform distribution of stresses along the coaptation edges of leaflets 22.
the angle at which force is transmitted to the commissures is increased, thereby substantially reducing the horizontal forces applied to the commissures that tend to pull the commissures away from the frame.
controlling the center of the height of coaptation allows the commissures to be located distal to the center of coaptation, thereby reducing the contracted delivery profile of the valve prosthesis.
All of the foregoing benefits are expected to reduce non-uniform loads applied to the valve body, and substantially enhance the durability of the valve prosthesis.
As will of course be apparent to one of skill in the art of prosthetic valve design, the assembly steps described above are merely illustrative, and a different order of assembling the leaflets and skirt to form valve body 14 may be employed. In an alternative embodiment, a conventional sewing ring may be attached to valve body 14 and frame 12 may be omitted. In this case, the valve prosthesis may be implanted surgically, rather than by percutaneous transluminal delivery. In this case, commissures 24 may be attached to the ascending aorta by sutures or other means as described above.
Referring now to
The delivery catheter and valve prosthesis are then advanced in a retrograde manner through a cut-down to the femoral artery and into the patient's descending aorta. The catheter then is advanced, under fluoroscopic guidance, over the aortic arch, through the ascending aorta and mid-way across the defective aortic valve. Once positioning of the catheter is confirmed, the sheath of the delivery catheter may be withdrawn proximally, thereby permitting the valve prosthesis to self-expand.
As the valve prosthesis expands, it traps native leaflets LN of the patient's defective aortic valve against the valve annulus, retaining the native valve in a permanently open state. As further illustrated in
As also seen in
Because outflow section 15 of frame 12 employs relatively larger cells than the remainder of the frame, valve prosthesis 10 does not disrupt blood flow into coronary arteries CA when deployed, and also does not obstruct subsequent catheter access to the coronary arteries. Accordingly, a clinician may readily gain access to the coronary arteries, for example, to perform angioplasty or stenting, simply by directing the angioplasty or stent delivery system guide wire through the openings in the cell pattern of frame 12.
While preferred embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.
This application is a continuation-in-part of U.S. patent application Ser. No. 11/128,826, filed May 13, 2005, now U.S. Pat. No. 7,914,569.
Number | Name | Date | Kind |
---|---|---|---|
3334629 | Cohn | Aug 1967 | A |
3409013 | Berry | Nov 1968 | A |
3540431 | Mobin-Uddin | Nov 1970 | A |
3587115 | Shiley | Jun 1971 | A |
3628535 | Ostrowsky et al. | Dec 1971 | A |
3642004 | Osthagen et al. | Feb 1972 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3714671 | Edwards et al. | Feb 1973 | A |
3755823 | Hancock | Sep 1973 | A |
3795246 | Sturgeon | Mar 1974 | A |
3839741 | Haller | Oct 1974 | A |
3868956 | Alfidi et al. | Mar 1975 | A |
3874388 | King et al. | Apr 1975 | A |
4035849 | Angell et al. | Jul 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4233690 | Akins | Nov 1980 | A |
4265694 | Boretos | May 1981 | A |
4291420 | Reul | Sep 1981 | A |
4297749 | Davis et al. | Nov 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4340977 | Brownlee et al. | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4345340 | Rosen | Aug 1982 | A |
4425908 | Simon | Jan 1984 | A |
4470157 | Love | Sep 1984 | A |
4501030 | Lane | Feb 1985 | A |
4574803 | Storz | Mar 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4592340 | Boyles | Jun 1986 | A |
4610688 | Silvestrini et al. | Sep 1986 | A |
4612011 | Kautzky | Sep 1986 | A |
4647283 | Carpentier et al. | Mar 1987 | A |
4648881 | Carpentier et al. | Mar 1987 | A |
4655771 | Wallsten | Apr 1987 | A |
4662885 | DiPisa, Jr. | May 1987 | A |
4665906 | Jervis | May 1987 | A |
4681908 | Broderick et al. | Jul 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4787901 | Baykut | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4819751 | Shimada et al. | Apr 1989 | A |
4833458 | Bowman | May 1989 | A |
4834755 | Silvestrini et al. | May 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4872874 | Taheri | Oct 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4909252 | Goldberger | Mar 1990 | A |
4917102 | Miller et al. | Apr 1990 | A |
4922905 | Strecker | May 1990 | A |
4954126 | Wallsten | Sep 1990 | A |
4966604 | Reiss | Oct 1990 | A |
4979939 | Shiber | Dec 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4994077 | Dobben | Feb 1991 | A |
5002559 | Tower | Mar 1991 | A |
5007896 | Shiber | Apr 1991 | A |
5026366 | Leckrone | Jun 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5047041 | Samuels | Sep 1991 | A |
5059177 | Towne et al. | Oct 1991 | A |
5061273 | Yock | Oct 1991 | A |
5085635 | Cragg | Feb 1992 | A |
5089015 | Ross | Feb 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5161547 | Tower | Nov 1992 | A |
5163953 | Vince | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5217483 | Tower | Jun 1993 | A |
5232445 | Bonzel | Aug 1993 | A |
5272909 | Nguyen et al. | Dec 1993 | A |
5295958 | Shurman | Mar 1994 | A |
5327774 | Nguyen et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5389106 | Tower | Feb 1995 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5415633 | Lazarus et al. | May 1995 | A |
5431676 | Dubrul et al. | Jul 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5480424 | Cox | Jan 1996 | A |
5489294 | McVenes et al. | Feb 1996 | A |
5489297 | Duran | Feb 1996 | A |
5496346 | Horzewski et al. | Mar 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5545211 | An et al. | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5580922 | Park et al. | Dec 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5667523 | Bynon et al. | Sep 1997 | A |
5674277 | Freitag | Oct 1997 | A |
5695498 | Tower | Dec 1997 | A |
5702368 | Stevens et al. | Dec 1997 | A |
5713953 | Vallana et al. | Feb 1998 | A |
5716417 | Girard et al. | Feb 1998 | A |
5746709 | Rom et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5782809 | Umeno et al. | Jul 1998 | A |
5800456 | Maeda et al. | Sep 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5817126 | Imran | Oct 1998 | A |
5824041 | Lenker | Oct 1998 | A |
5824043 | Cottone, Jr. | Oct 1998 | A |
5824053 | Khosravi et al. | Oct 1998 | A |
5824056 | Rosenberg | Oct 1998 | A |
5824061 | Quijano et al. | Oct 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5843158 | Lenker et al. | Dec 1998 | A |
5851232 | Lois | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5860966 | Tower | Jan 1999 | A |
5861028 | Angell | Jan 1999 | A |
5868783 | Tower | Feb 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5888201 | Stinson et al. | Mar 1999 | A |
5891191 | Stinson | Apr 1999 | A |
5906619 | Olson et al. | May 1999 | A |
5907893 | Zadno-Azizi et al. | Jun 1999 | A |
5913842 | Boyd et al. | Jun 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5968068 | Dehdashtian et al. | Oct 1999 | A |
5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
5997573 | Quijano et al. | Dec 1999 | A |
6022370 | Tower | Feb 2000 | A |
6027525 | Suh et al. | Feb 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6042589 | Marianne | Mar 2000 | A |
6042598 | Tsugita et al. | Mar 2000 | A |
6042607 | Williamson, IV | Mar 2000 | A |
6051014 | Jang | Apr 2000 | A |
6059809 | Amor et al. | May 2000 | A |
6110201 | Quijano et al. | Aug 2000 | A |
6146366 | Schachar | Nov 2000 | A |
6159239 | Greenhalgh | Dec 2000 | A |
6162208 | Hipps | Dec 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6200336 | Pavcnik et al. | Mar 2001 | B1 |
6203550 | Olson | Mar 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6218662 | Tchakarov et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6241757 | An et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6248116 | Chevillon et al. | Jun 2001 | B1 |
6258114 | Konya et al. | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258120 | McKenzie et al. | Jul 2001 | B1 |
6277555 | Duran et al. | Aug 2001 | B1 |
6299637 | Shaolian et al. | Oct 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6309382 | Garrison et al. | Oct 2001 | B1 |
6309417 | Spence et al. | Oct 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
6338735 | Stevens | Jan 2002 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6352708 | Duran et al. | Mar 2002 | B1 |
6371970 | Khosravi et al. | Apr 2002 | B1 |
6371983 | Lane | Apr 2002 | B1 |
6379383 | Palmaz et al. | Apr 2002 | B1 |
6380457 | Yurek et al. | Apr 2002 | B1 |
6398807 | Chouinard et al. | Jun 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | Di Matteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6468303 | Amplatz et al. | Oct 2002 | B1 |
6475239 | Campbell et al. | Nov 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6494909 | Greenhalgh | Dec 2002 | B2 |
6503272 | Duerig et al. | Jan 2003 | B2 |
6503274 | Howanec et al. | Jan 2003 | B1 |
6508833 | Pavcnik et al. | Jan 2003 | B2 |
6527800 | McGuckin, Jr. et al. | Mar 2003 | B1 |
6530949 | Konya et al. | Mar 2003 | B2 |
6530952 | Vesely | Mar 2003 | B2 |
6562031 | Chandrasekaran et al. | May 2003 | B2 |
6562058 | Seguin et al. | May 2003 | B2 |
6562069 | Cai et al. | May 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6585758 | Chouinard et al. | Jul 2003 | B1 |
6585766 | Huynh et al. | Jul 2003 | B1 |
6592546 | Barbut et al. | Jul 2003 | B1 |
6605112 | Moll et al. | Aug 2003 | B1 |
6613077 | Gilligan et al. | Sep 2003 | B2 |
6622604 | Chouinard et al. | Sep 2003 | B1 |
6632243 | Zadno-Azizi et al. | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6652571 | White et al. | Nov 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6656213 | Solem | Dec 2003 | B2 |
6663663 | Kim et al. | Dec 2003 | B2 |
6669724 | Park et al. | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6673109 | Cox | Jan 2004 | B2 |
6676698 | McGuckin, Jr. et al. | Jan 2004 | B2 |
6682558 | Tu et al. | Jan 2004 | B2 |
6682559 | Myers et al. | Jan 2004 | B2 |
6685739 | DiMatteo et al. | Feb 2004 | B2 |
6689144 | Gerberding | Feb 2004 | B2 |
6689164 | Seguin | Feb 2004 | B1 |
6692512 | Jang | Feb 2004 | B2 |
6692513 | Streeter et al. | Feb 2004 | B2 |
6695878 | McGuckin, Jr. et al. | Feb 2004 | B2 |
6702851 | Chinn et al. | Mar 2004 | B1 |
6719789 | Cox | Apr 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6730377 | Wang | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6736846 | Cox | May 2004 | B2 |
6752828 | Thornton | Jun 2004 | B2 |
6758855 | Fulton, III et al. | Jul 2004 | B2 |
6769434 | Liddicoat et al. | Aug 2004 | B2 |
6786925 | Schoon | Sep 2004 | B1 |
6790229 | Berreklouw | Sep 2004 | B1 |
6792979 | Konya et al. | Sep 2004 | B2 |
6797002 | Spence | Sep 2004 | B2 |
6821297 | Snyders | Nov 2004 | B2 |
6830575 | Stenzel et al. | Dec 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6830585 | Artof | Dec 2004 | B1 |
6846325 | Liddicoat | Jan 2005 | B2 |
6866650 | Stevens et al. | Mar 2005 | B2 |
6872223 | Roberts | Mar 2005 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6883522 | Spence et al. | Apr 2005 | B2 |
6887266 | Williams et al. | May 2005 | B2 |
6890330 | Streeter et al. | May 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6908481 | Cribier | Jun 2005 | B2 |
6913600 | Valley et al. | Jul 2005 | B2 |
6929653 | Streeter | Aug 2005 | B2 |
6936066 | Palmaz et al. | Aug 2005 | B2 |
6939365 | Fogarty et al. | Sep 2005 | B1 |
6951571 | Srivastava | Oct 2005 | B1 |
6986742 | Hart et al. | Jan 2006 | B2 |
6989027 | Allen et al. | Jan 2006 | B2 |
6989028 | Lashinski et al. | Jan 2006 | B2 |
6991649 | Sievers | Jan 2006 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7041128 | McGuckin, Jr. et al. | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7048014 | Hyodoh et al. | May 2006 | B2 |
7097659 | Woolfson et al. | Aug 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7105016 | Shiu et al. | Sep 2006 | B2 |
7115141 | Menz et al. | Oct 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7153324 | Case et al. | Dec 2006 | B2 |
7160319 | Chouinard et al. | Jan 2007 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201761 | Woolfson et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7300457 | Palmaz | Nov 2007 | B2 |
7300463 | Liddicoat | Nov 2007 | B2 |
7316706 | Bloom et al. | Jan 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7335218 | Wilson et al. | Feb 2008 | B2 |
7338520 | Bailey et al. | Mar 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7384411 | Condado | Jun 2008 | B1 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7470284 | Lambrecht et al. | Dec 2008 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7544206 | Cohn et al. | Jun 2009 | B2 |
7556646 | Yang et al. | Jul 2009 | B2 |
20010001314 | Davison et al. | May 2001 | A1 |
20010002445 | Vesely | May 2001 | A1 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010011189 | Drasler et al. | Aug 2001 | A1 |
20010021872 | Bailey | Sep 2001 | A1 |
20010025196 | Chinn et al. | Sep 2001 | A1 |
20010032013 | Marton | Oct 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20010041928 | Pavcnik et al. | Nov 2001 | A1 |
20010044647 | Pinchuk et al. | Nov 2001 | A1 |
20010049555 | Gabbay | Dec 2001 | A1 |
20020010508 | Chobotov | Jan 2002 | A1 |
20020029014 | Jayaraman | Mar 2002 | A1 |
20020032480 | Spence et al. | Mar 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020035396 | Heath | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020042651 | Liddicoat et al. | Apr 2002 | A1 |
20020052651 | Myers et al. | May 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020072789 | Hackett et al. | Jun 2002 | A1 |
20020077696 | Zadno-Azizi et al. | Jun 2002 | A1 |
20020095209 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020099439 | Schwartz et al. | Jul 2002 | A1 |
20020103533 | Langberg et al. | Aug 2002 | A1 |
20020107565 | Greenhalgh | Aug 2002 | A1 |
20020111674 | Chouinard et al. | Aug 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020133183 | Lentz et al. | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020161392 | Dubrul | Oct 2002 | A1 |
20020161394 | Macoviak et al. | Oct 2002 | A1 |
20020193871 | Beyersdorf et al. | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030028247 | Cali | Feb 2003 | A1 |
20030036791 | Philipp et al. | Feb 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030065386 | Weadock | Apr 2003 | A1 |
20030069492 | Abrams et al. | Apr 2003 | A1 |
20030069636 | Solem et al. | Apr 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030125795 | Pavcnik et al. | Jul 2003 | A1 |
20030130726 | Thorpe et al. | Jul 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030139804 | Hankh et al. | Jul 2003 | A1 |
20030149475 | Hyodoh et al. | Aug 2003 | A1 |
20030149476 | Damm et al. | Aug 2003 | A1 |
20030149478 | Figulla et al. | Aug 2003 | A1 |
20030153974 | Spenser et al. | Aug 2003 | A1 |
20030181850 | Diamond et al. | Sep 2003 | A1 |
20030191519 | Lombardi et al. | Oct 2003 | A1 |
20030199913 | Dubrul et al. | Oct 2003 | A1 |
20030199963 | Tower et al. | Oct 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20030199972 | Zadno-Azizi et al. | Oct 2003 | A1 |
20030212410 | Stenzel et al. | Nov 2003 | A1 |
20030212452 | Zadno-Azizi et al. | Nov 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040049224 | Buehlmann et al. | Mar 2004 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040049266 | Anduiza et al. | Mar 2004 | A1 |
20040082904 | Houde et al. | Apr 2004 | A1 |
20040088045 | Cox | May 2004 | A1 |
20040093005 | Durcan | May 2004 | A1 |
20040093060 | Sequin et al. | May 2004 | A1 |
20040097788 | Mourlas et al. | May 2004 | A1 |
20040098112 | DiMatteo et al. | May 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040106990 | Spence et al. | Jun 2004 | A1 |
20040111096 | Tu et al. | Jun 2004 | A1 |
20040116951 | Rosengart | Jun 2004 | A1 |
20040117004 | Osborne et al. | Jun 2004 | A1 |
20040122468 | Yodfat et al. | Jun 2004 | A1 |
20040122516 | Fogarty | Jun 2004 | A1 |
20040127979 | Wilson | Jul 2004 | A1 |
20040138742 | Myers et al. | Jul 2004 | A1 |
20040138743 | Myers et al. | Jul 2004 | A1 |
20040153146 | Lashinski et al. | Aug 2004 | A1 |
20040167573 | Williamson | Aug 2004 | A1 |
20040167620 | Ortiz | Aug 2004 | A1 |
20040186563 | Iobbi | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040210240 | Saint | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040215333 | Duran | Oct 2004 | A1 |
20040215339 | Drasler et al. | Oct 2004 | A1 |
20040225353 | McGuckin, Jr. | Nov 2004 | A1 |
20040225354 | Allen | Nov 2004 | A1 |
20040254636 | Flagle et al. | Dec 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20040267357 | Allen et al. | Dec 2004 | A1 |
20050010246 | Streeter | Jan 2005 | A1 |
20050010285 | Lambrecht et al. | Jan 2005 | A1 |
20050010287 | Macoviak | Jan 2005 | A1 |
20050015112 | Cohn et al. | Jan 2005 | A1 |
20050027348 | Case et al. | Feb 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050049692 | Numamoto | Mar 2005 | A1 |
20050049696 | Siess | Mar 2005 | A1 |
20050055088 | Liddicoat et al. | Mar 2005 | A1 |
20050060029 | Le et al. | Mar 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075712 | Biancucci | Apr 2005 | A1 |
20050075717 | Nguyen | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075724 | Svanidze | Apr 2005 | A1 |
20050075725 | Rowe | Apr 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050075730 | Myers | Apr 2005 | A1 |
20050075731 | Artof | Apr 2005 | A1 |
20050085841 | Eversull et al. | Apr 2005 | A1 |
20050085842 | Eversull et al. | Apr 2005 | A1 |
20050085843 | Opolski et al. | Apr 2005 | A1 |
20050085890 | Rasmussen et al. | Apr 2005 | A1 |
20050085900 | Case et al. | Apr 2005 | A1 |
20050096568 | Kato | May 2005 | A1 |
20050096692 | Linder et al. | May 2005 | A1 |
20050096724 | Stenzel et al. | May 2005 | A1 |
20050096727 | Allen et al. | May 2005 | A1 |
20050096734 | Majercak et al. | May 2005 | A1 |
20050096735 | Hojeibane et al. | May 2005 | A1 |
20050096736 | Osse et al. | May 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050107871 | Realyvasquez et al. | May 2005 | A1 |
20050113910 | Paniagua | May 2005 | A1 |
20050119688 | Bergheim | Jun 2005 | A1 |
20050131438 | Cohn | Jun 2005 | A1 |
20050137686 | Salahieh | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug | Jun 2005 | A1 |
20050137695 | Salahieh | Jun 2005 | A1 |
20050137701 | Salahieh | Jun 2005 | A1 |
20050143809 | Salahieh | Jun 2005 | A1 |
20050148997 | Valley et al. | Jul 2005 | A1 |
20050149181 | Eberhardt | Jul 2005 | A1 |
20050165477 | Anduiza et al. | Jul 2005 | A1 |
20050187616 | Realyvasquez | Aug 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050203605 | Dolan | Sep 2005 | A1 |
20050203618 | Sharkawy | Sep 2005 | A1 |
20050222674 | Paine | Oct 2005 | A1 |
20050228495 | Macoviak | Oct 2005 | A1 |
20050234546 | Nugent | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050240263 | Fogarty et al. | Oct 2005 | A1 |
20050261759 | Lambrecht et al. | Nov 2005 | A1 |
20050283962 | Boudjemline | Dec 2005 | A1 |
20060004439 | Spenser et al. | Jan 2006 | A1 |
20060009841 | McGuckin et al. | Jan 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058775 | Stevens et al. | Mar 2006 | A1 |
20060089711 | Dolan | Apr 2006 | A1 |
20060100685 | Seguin et al. | May 2006 | A1 |
20060116757 | Lashinski et al. | Jun 2006 | A1 |
20060135964 | Vesely | Jun 2006 | A1 |
20060142848 | Gabbay | Jun 2006 | A1 |
20060167474 | Bloom et al. | Jul 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060206192 | Tower et al. | Sep 2006 | A1 |
20060206202 | Bonhoeffer et al. | Sep 2006 | A1 |
20060247763 | Slater | Nov 2006 | A1 |
20060259134 | Schwammenthal et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060271166 | Thill et al. | Nov 2006 | A1 |
20060271175 | Woolfson et al. | Nov 2006 | A1 |
20060276874 | Wilson et al. | Dec 2006 | A1 |
20060282161 | Huynh et al. | Dec 2006 | A1 |
20070005129 | Damm et al. | Jan 2007 | A1 |
20070005131 | Taylor | Jan 2007 | A1 |
20070010878 | Rafiee et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070027518 | Case et al. | Feb 2007 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070051377 | Douk et al. | Mar 2007 | A1 |
20070073392 | Heyninck-Jantz | Mar 2007 | A1 |
20070078509 | Lotfy et al. | Apr 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070088431 | Bourang et al. | Apr 2007 | A1 |
20070093869 | Bloom et al. | Apr 2007 | A1 |
20070100439 | Cangialosi | May 2007 | A1 |
20070100440 | Figulla | May 2007 | A1 |
20070100449 | O'Neil et al. | May 2007 | A1 |
20070112415 | Barlett | May 2007 | A1 |
20070162102 | Ryan et al. | Jul 2007 | A1 |
20070162113 | Sharkawy et al. | Jul 2007 | A1 |
20070185513 | Woolfson et al. | Aug 2007 | A1 |
20070203391 | Bloom et al. | Aug 2007 | A1 |
20070225681 | House | Sep 2007 | A1 |
20070232898 | Huynh et al. | Oct 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070233237 | Krivoruchko | Oct 2007 | A1 |
20070233238 | Huynh et al. | Oct 2007 | A1 |
20070238979 | Huynh et al. | Oct 2007 | A1 |
20070239254 | Marchand et al. | Oct 2007 | A1 |
20070239265 | Birdsall | Oct 2007 | A1 |
20070239266 | Birdsall | Oct 2007 | A1 |
20070239269 | Dolan et al. | Oct 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070244544 | Birdsall et al. | Oct 2007 | A1 |
20070244545 | Birdsall et al. | Oct 2007 | A1 |
20070244546 | Francis | Oct 2007 | A1 |
20070244553 | Rafiee et al. | Oct 2007 | A1 |
20070244554 | Rafiee et al. | Oct 2007 | A1 |
20070244555 | Rafiee et al. | Oct 2007 | A1 |
20070244556 | Rafiee et al. | Oct 2007 | A1 |
20070244557 | Rafiee et al. | Oct 2007 | A1 |
20070250160 | Rafiee | Oct 2007 | A1 |
20070255394 | Ryan | Nov 2007 | A1 |
20070255396 | Douk et al. | Nov 2007 | A1 |
20070288000 | Bonan | Dec 2007 | A1 |
20080004696 | Vesely | Jan 2008 | A1 |
20080009940 | Cribier | Jan 2008 | A1 |
20080015671 | Bonhoeffer | Jan 2008 | A1 |
20080021552 | Gabbay | Jan 2008 | A1 |
20080048656 | Tan | Feb 2008 | A1 |
20080065011 | Marchand et al. | Mar 2008 | A1 |
20080065206 | Liddicoat | Mar 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071362 | Tuval et al. | Mar 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071368 | Tuval et al. | Mar 2008 | A1 |
20080077234 | Styrc | Mar 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080133003 | Seguin et al. | Jun 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147105 | Wilson et al. | Jun 2008 | A1 |
20080147180 | Ghione et al. | Jun 2008 | A1 |
20080147181 | Ghione et al. | Jun 2008 | A1 |
20080147182 | Righini et al. | Jun 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080161910 | Revuelta et al. | Jul 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080183273 | Mesana et al. | Jul 2008 | A1 |
20080188928 | Salahieh et al. | Aug 2008 | A1 |
20080215143 | Seguin | Sep 2008 | A1 |
20080215144 | Ryan et al. | Sep 2008 | A1 |
20080228254 | Ryan | Sep 2008 | A1 |
20080228263 | Ryan | Sep 2008 | A1 |
20080234797 | Styrc | Sep 2008 | A1 |
20080243246 | Ryan et al. | Oct 2008 | A1 |
20080255651 | Dwork | Oct 2008 | A1 |
20080255660 | Guyenot et al. | Oct 2008 | A1 |
20080255661 | Straubinger et al. | Oct 2008 | A1 |
20080262593 | Ryan et al. | Oct 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090012600 | Styrc et al. | Jan 2009 | A1 |
20090048656 | Wen | Feb 2009 | A1 |
20090054976 | Tuval et al. | Feb 2009 | A1 |
20090069886 | Suri et al. | Mar 2009 | A1 |
20090069887 | Righini et al. | Mar 2009 | A1 |
20090069889 | Suri et al. | Mar 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090164004 | Cohn | Jun 2009 | A1 |
20090171447 | VonSegesser et al. | Jul 2009 | A1 |
20090192585 | Bloom et al. | Jul 2009 | A1 |
20090192586 | Tabor et al. | Jul 2009 | A1 |
20090192591 | Ryan et al. | Jul 2009 | A1 |
20090198316 | Laske et al. | Aug 2009 | A1 |
20090216310 | Straubinger et al. | Aug 2009 | A1 |
20090216312 | Straubinger et al. | Aug 2009 | A1 |
20090216313 | Straubinger et al. | Aug 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100131054 | Tuval et al. | May 2010 | A1 |
20100137979 | Tuval et al. | Jun 2010 | A1 |
Number | Date | Country |
---|---|---|
101011298 | Aug 2007 | CN |
19532846 | Mar 1997 | DE |
195 46692 | Jun 1997 | DE |
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
19907646 | Aug 2000 | DE |
10-049814 | Apr 2002 | DE |
10-049815 | Apr 2002 | DE |
10049812 | Apr 2002 | DE |
10049813 | Apr 2002 | DE |
0 103 546 | Mar 1984 | EP |
0 103 546 | Mar 1984 | EP |
0 597 967 | Dec 1994 | EP |
0 850 607 | Jul 1998 | EP |
1057459 | Jun 2000 | EP |
1 057 460 | Dec 2000 | EP |
1 088 529 | Apr 2001 | EP |
1255510 | Nov 2002 | EP |
0937439 | Sep 2003 | EP |
1340473 | Sep 2003 | EP |
0819013 | Jun 2004 | EP |
1 271 508 | Nov 1986 | FR |
2 788 217 | Jul 2000 | FR |
2 056 023 | Mar 1981 | GB |
2433700 | Dec 2007 | GB |
WO 9117720 | Nov 1991 | WO |
WO 9217118 | Oct 1992 | WO |
WO 9301768 | Feb 1993 | WO |
WO 9318721 | Sep 1993 | WO |
9529640 | Nov 1995 | WO |
9814137 | Apr 1998 | WO |
WO 9829057 | Jul 1998 | WO |
WO 9933414 | Jul 1999 | WO |
WO 0041652 | Jul 2000 | WO |
0044313 | Aug 2000 | WO |
0047136 | Aug 2000 | WO |
WO 0047139 | Aug 2000 | WO |
WO 0106959 | Feb 2001 | WO |
WO 0135870 | May 2001 | WO |
WO 0149213 | Jul 2001 | WO |
WO0149213 | Jul 2001 | WO |
WO 0154625 | Aug 2001 | WO |
WO 0162189 | Aug 2001 | WO |
WO 0164137 | Sep 2001 | WO |
WO 0176510 | Oct 2001 | WO |
WO 0222054 | May 2002 | WO |
WO 0236048 | May 2002 | WO |
WO 0241789 | May 2002 | WO |
WO 0243620 | Jun 2002 | WO |
WO 0247575 | Jun 2002 | WO |
WO 0249540 | Jun 2002 | WO |
03003943 | Jan 2003 | WO |
03003949 | Jan 2003 | WO |
03011195 | Feb 2003 | WO |
03030776 | Apr 2003 | WO |
WO03047468 | Jun 2003 | WO |
WO2004016200 | Feb 2004 | WO |
2004019811 | Mar 2004 | WO |
2004019825 | Mar 2004 | WO |
2004023980 | Mar 2004 | WO |
2004041126 | May 2004 | WO |
2004058106 | Jul 2004 | WO |
2004089250 | Oct 2004 | WO |
2005004753 | Jan 2005 | WO |
2005011534 | Feb 2005 | WO |
2005027790 | Mar 2005 | WO |
2005046528 | May 2005 | WO |
2008047354 | Apr 2008 | WO |
2008100599 | Aug 2008 | WO |
2008150529 | Dec 2008 | WO |
2009002548 | Dec 2008 | WO |
2009029199 | Mar 2009 | WO |
2009042196 | Apr 2009 | WO |
2009061389 | May 2009 | WO |
2009091509 | Jul 2009 | WO |
Entry |
---|
Balloon-Expandable Intracoronary Stent in the Adult Dog; Schatz, Richard MD et al.; Laboratory Investigation—Myocardial Ischemia, pp. 450-457 (1987). |
Pelton et al, Medical Uses of Nitinol, Materials Science Forum vols. 327-2328 pp. 63-70. (2000). |
U.S. Appl. No. 12/050,184, filed Mar. 18, 2008. |
U.S. Appl. No. 12/050,628, filed Mar. 18, 2008. |
U.S. Appl. No. 12/248,776, filed Oct. 9, 2008. |
U.S. Appl. No. 12/250,163, filed Oct. 13, 2008. |
U.S. Appl. No. 61/192,199, filed Sep. 15, 2008. |
U.S. Appl. No. 12/253,858, filed Oct. 17, 2008. |
U.S. Appl. No. 60/907,907, filed Apr. 20, 2007. |
U.S. Appl. No. 61/129,170, filed Jun. 9, 2008. |
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J. (1992) 13:704-708. |
Babaliaros, et al., “State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair,” Cardiology 2007; 107:87-96. |
Bailey, “Percutaneous Expandable Prosthetic Valves,” In: Topol EJ, ed. Textbook of Interventional Cardiology. vol. II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276. |
Block, et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, vol. 7 (2005) pp. 108-113. |
Bonhoeffer, et al, “Percutaneous Insertion of the Pulmonary Valve,” Journal of the American College of Cardiology (United States), May 15, 2002, pp. 1664-1669. |
Bonhoeffer, et al, “Percutaneous Mitral Valve Dilatation with the Multi-Track System,” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Oct. 1999, pp. 178-183. |
Bonhoeffer, et al, “Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction,” Lancet (England), Oct. 21, 2000, pp. 1403-1405. |
Bonhoeffer, et al, “Technique and Results of Percutaneous Mitral Valvuloplasty With the Multi-Track System,” Journal of Interventional Cardiology (United States), 200, pp. 263-268. |
Bonhoeffer, et al, “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation (United States), Aug. 15, 2000, pp. 813-816. |
Boudjemline, et al, “Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals,” Circulation (United States), Mar. 16, 2004, 109, p. e161. |
Boudjemline, et al, “Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Mar. 2004, pp. BR61-6. |
Boudjemline, et al, “Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: A Hybrid Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Apr. 2005, pp. 831-837. |
Boudjemline, et al, “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706. |
Boudjemline, et al, “Percutaneous Closure of a Paravalvular Mitral Regurgitation with Amplatzer and Coil Prostheses,” Archives des Maladies du Coeur Et Des Vaisseaux (France), May 2002, pp. 483-486. |
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study,” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-6. |
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal 22, Sep. 2001, p. 630. |
Boudjemline, et al, “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs,” European Heart Journal (England), Jul. 2002, pp. 1045-1049. |
Boudjemline, et al, “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study,” Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087. |
Boudjemline, et al, “Percutaneous Valve Insertion: A New Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742. |
Boudjemline, et al, “Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits,” European Heart Journal 22, Sep. 2001, p. 355. |
Boudjemline, et al, “Steps Toward Percutaneous Aortic Valve Replacement,” Circulation (United States), Feb. 12, 2002, pp. 775-778. |
Boudjemline, et al, “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93. |
Boudjemline, et al, “Transcatheter Reconstruction of the Right Heart,” Cardiology in the Young (England), Jun. 2003, pp. 308-311. |
Coats, et al, “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543. |
Cribier, A. et al, “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description,” Circulation (2002) 3006-3008. |
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15 (2006) 123-129. |
Hanzel, et al., “Complications of percutaneous aortic valve replacement: experience with the Criber-Edwards™ percutaneous heart valve,” Eurolntervention Supplements (2006), 1 (Supplement A) A3-A8. |
Huber, et al., “Do Valved Stents Compromise Coronary Flow?” Eur. J. Cardiothorac. Surg. 2004;25:754-759. |
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408. |
Khambadkone, et al, “Percutaneous Implantation of Pulmonary Valves,” Expert Review of Cardiovascular Therapy (England); Nov. 2003, pp. 541-548. |
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375. |
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Impact of Morphology on Case Selection,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-642-1V-643. |
Lutter, et al, “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776. |
Lutter, et al, “Percutaneous Valve Replacement: Current State and Future Prospects,” Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206. |
Medtech Insight, “New Frontiers in Heart Valve Disease,” vol. 7, No. 8 (2005). |
Palacios, “Percutaneous Valve Replacement and Repair, Fiction or Reality?” Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663. |
Ruiz, “Transcathether Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, vol. 26, No. 3 (2005). |
Saliba, et al, “Treatment of Obstructions of Prosthetic Conduits by Percutaneous Implantation of Stents,” Archives des Maldies du Coeur et des Vaisseaux (France), 1999, pp. 591-596. |
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation (2006), 113;842-850. |
Yonga, et al, “Effect of Percutaneous Balloon-Mitral Valvotomy on Pulmonary Venous Flow in Severe Mitral Stenosis,” East African Medical Journal (Kenya), Jan. 1999, pp. 28-30. |
Yonga, et al, “Percutaneous Balloon Mitral Valvotomy: Initial Experience in Nairobi Using a New Multi-Track Catheter System,” East African Medical Journal (Kenya), Feb. 1999, pp. 71-74. |
Yonga, et al, “Percutaneous Transluminal Balloon Valvuloplasty for Pulmonary Valve Stenosis: Report on Six Cases,” East African Medical Journal (Kenya), Apr. 1994, pp. 232-235. |
Yonga, et al, “Percutaneous Transvenous Mitral Commissurotomy in Juvenile Mitral Stenosis,” East African Medical Journal (Kenya), Apr. 2003, pp. 172-174. |
Commeau et al, “Percutaneous balloon dilatation of calcific aortic valve stenosis: anatomical and haemodynamic evaluation,” 1988, British Heart Journal, 59:227-238. |
Stassano et al., “Mid-term results of the valve-on-valve technique for bioprosthetic failure,” Eur. J. Cardiothorac. Surg. 2000; 18:453-457. |
Expert report of Dr. Nigel Buller, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Expert report of Dr. Nigel Buller, non-confidential annex—infringement, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Expert report of Dr. Rodolfo Quijano, dated Jan. 9, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
First Expert report of Prof. David Williams, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
First Expert report of Prof. Martin Rothman, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Fourth Expert report of Prof. Martin Rothman, dated Apr. 22, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Second Expert report of Dr. Nigel Buller, dated Feb. 25, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Second Expert report of Dr. Rodolfo Quijano, dated Feb. 26, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Second Expert report of Prof. David Williams, dated Feb. 5, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Second Expert report of Prof. Martin Rothman, dated Feb. 5, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Third Expert report of Dr. Nigel Buller, dated Apr. 21, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Third Expert report of Dr. Rudolfo Quijano, dated Apr. 27, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Third Expert report of Prof. David Williams, dated Apr. 22, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934. |
Pavcnik et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Techol. 2000, vol. 9, pp. 287-292. |
First Expert report of Dr. Nigel Person Buller (30 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Second Expert report of Dr. Nigel Person Buller (5 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice —Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Drawing by Dr. Buller (Edwards Expert) of his interpretation of the “higher stent” referred to at col. 8, lines 13-222 of Andersen EP 592410B1 (1 page), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Drawing by Dr. Buller (Edwards Expert) of “higher stent” on the schematic representation of the aortic valve area set out in Figure 2 of Rothman's first expert report (1 page), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Expert report of Professor John R. Pepper (20 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Second Expert report of Professor John R. Pepper (3 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Expert report of Dr. Anthony C. Lunn (7 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Witness statement of Stanton Rowe (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Second Witness statement of Stanton Rowe (3 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
PVT slides naming Alain Cribier, Martin Leon, Stan Rabinovich and Stanton Rowe (16 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Expert report of Professor Martin Terry Rothman (75 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Reply Expert report of Professor Martin Terry Rothman (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Expert report of Richard A. Hillstead (41 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Reply Expert report of Richard A. Hillstead (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
U.S. Appl. No. 10/772,101, filed Feb. 4, 2004. |
U.S. Appl. No. 11/434,506, filed May 15, 2006. |
U.S. Appl. No. 11/829,682, filed Jul. 27, 2007. |
U.S. Appl. No. 11/488,395, filed Jul. 18, 2006. |
U.S. Appl. No. 11/952,080, filed Dec. 6, 2007. |
Number | Date | Country | |
---|---|---|---|
20060265056 A1 | Nov 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11128826 | May 2005 | US |
Child | 11433296 | US |